The Role of Marplan® (isocarboxazid) Tablets in Alleviating the Symptoms of Treatment-Resistant* Depression
Psychotherapy and standard antidepressant medications can alleviate depression symptoms for many patients in a period of weeks or just a few months.
If depression lasts for a more extended period of time, patients may experience a profound sense of frustration over their chronic (long-term) lack of symptom relief. Social withdrawal and an overwhelming feeling of hopelessness and despair may continue after years of incomplete symptom control.
When a patient’s symptoms don’t respond to one or more conventional antidepressants, the patient’s condition is called treatment-resistant depression9*—but there is still hope, and treatment is available:
- Patients with this condition may respond favorably to a different chemical class of mood-elevating drugs called MAO inhibitors5
- Marplan® (isocarboxazid) Tablets are an effective MAO inhibitor2,9
These studies demonstrate a decrease in depressed symptoms vs. placebo over a 6-week period.
Adverse Findings Observed in Short-Term, Placebo-Controlled Trials
The commonly observed adverse events that occurred in Marplan patients with an incidence of 5% or greater and at least twice the incidence in placebo patients were nausea, dry mouth, and dizziness.
Clinical Worsening and Suicide Risk:
Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults with MDD and other psychiatric disorders in short-term studies. Anyone considering the use of Marplan or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.
Marplan is not approved for use in pediatric patients.
Families and caregivers should be advised of the need for close observation and communication with the prescriber. Marplan is not approved for treating bipolar depression.
*Treatment failure with first-line antidepressants.
Please click here to review the Marplan references.